GoodRx Holdings Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Class A and Class BCommon Stock · AdditionalPaid-in Capital · Accumulated Deficit · TotalStockholders' Equity | |||||
|---|---|---|---|---|---|
| (in thousands) · Shares · Amount | |||||
| Balance at December 31, 2023 | 394,087 | $40 | $2,219,321 | $(1,457,403) | $761,958 |
| Stock options exercised | 604 | — | 2,666 | — | 2,666 |
| Stock-based compensation | — | — | 28,891 | — | 28,891 |
| Vesting and settlement of restricted stock units | 2,535 | — | — | — | — |
| Common stock withheld related to net share settlement | (954) | — | (6,623) | — | (6,623) |
| Repurchases of Class A common stock (1) | (21,329) | (2) | (154,812) | — | (154,814) |
| Net loss | — | — | — | (1,009) | (1,009) |
| Balance at March 31, 2024 | 374,943 | $38 | $2,089,443 | $(1,458,412) | $631,069 |
(1)Repurchases of Class A common stock for the three months ended March 31, 2024 include 20.9 million shares
repurchased from related parties (after giving effect to the automatic conversion of Class B common stock to Class
A common stock upon such repurchase) for an aggregate considerationof $151.4 million. See "Note 9.
Stockholders' Equity" for additional information.
Condensed Consolidated Statements of Stockholders’ Equity
| Class A and Class BCommon Stock · AdditionalPaid-in Capital · Accumulated Deficit · TotalStockholders' Equity | |||||
|---|---|---|---|---|---|
| (in thousands) · Shares · Amount | |||||
| Balance at December 31, 2022 | 397,025 | $40 | $2,263,322 | $(1,448,535) | $814,827 |
| Stock options exercised | 192 | — | 895 | — | 895 |
| Stock-based compensation | — | — | 28,263 | — | 28,263 |
| Vesting and settlement of restricted stock units | 1,668 | — | — | — | — |
| Common stock withheld related to net share settlement | (666) | — | (3,710) | — | (3,710) |
| Repurchases of Class A common stock | (1,570) | — | (9,517) | — | (9,517) |
| Net loss | — | — | — | (3,290) | (3,290) |
| Balance at March 31, 2023 | 396,649 | $40 | $2,279,253 | $(1,451,825) | $827,468 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.